Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0110
Trial ID NCT01318317
Disease Non-Hodgkin's Lymphoma
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19 CAR-T cells
Co-treatment peripheral blood stem cell transplant
Generation1st|2nd
PhasePhase1|Phase2
Recruitment statusActive, Not Recruiting
TitleGenetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
Year2011
CountryUnited States
Company sponsorCity of Hope Medical Center
Other ID(s)09174|NCI-2011-00344|09174|P30CA033572|P50CA107399
Vector information
Vectorlentivirus
ConstructscFv-CD3ζ|scFv-CD28-CD3ζ
Vector typeself-inactivating lentiviral vector pHIV7
Transgene/Inserted geneVH and VL gene segments (scFv) of the CD19-specific FMC63 monoclonal antibody (mAb); IgG4 hinge-CH2-CH3; signaling domains CD3ζ (CD19CAR)
Regulatory elementEF-1 promoter
Viral genome modificationThe CD19R:ζ DNA sequence (optimized by GeneArt) was cloned into a self-inactivating lentiviral vector pHIV7 that has an EF-1 promoter.
Vector production methodThe huEGFRt was synthesized by PCR splice overlap extension to fuse in frame the human granulocyte-macrophage-colony-stimulating factor receptor's leader peptide to domains III and IV and the transmembrane spanning components of huEGFR (base pairs, 1000-2004). This fusion product was then cloned into the epHIV7 vector (in which the cytomegalovirus promoter of pHIV7 was replaced with an EF-1 promoter) along with the CD19CAR and T2A sequences, and the final construct was confirmed by sequence analysis.
Additional featureEGFRt|cytoplasmic domain of the CD3ζ chain|CD28 costimulatory domain|self-cleaving T2A sequence

Clinical Result

Cohort1: CD19R: ζ
Administration route None
Dosage 50E6 cells, 100E6 cells, 500E6 cells, 1000E6 cells
Donor type Autologous
Pts 8
Age Adult, Older_Adult
Outcome 5/8(CR); 2/8(PR); 1/8(PD); 4/8 patients (50%; 95% confidence interval [CI]: 16-84%) were progression free at both 1 and 2 years
References PMID: 27118452
Cohort2: CD19R: CD28: ζ
Administration route None
Dosage 50E6 cells, 200E6 cells, 800E6 cells
Donor type Autologous
Pts 8
Age Adult, Older_Adult
Outcome 8/8(CR). 6 patients (75%; 95% CI: 35-97%) were progression free at 1 year.
References PMID: 27118452

Relationship Graph

Overview of Knowledge Graph